Vir Biotechnology, Inc.

Vir Biotechnology is developing functional cure strategies for chronic infectious diseases, with VIR-2218 (RNAi for HBV) in Phase 3 and VIR-3434 (HBV antibody) as key pipeline assets. Its 23 trials include 6 Phase 1, 7 Phase 2, and 2 Phase 3 studies. With only 4 insider transactions, the HBV Phase 3 data timeline and partnership activity (Brii Biosciences, Alnylam) are the primary catalysts. A functional HBV cure would address a 300M+ person global market with no current complete cure.

<article class="bts-verified-summary" data-ticker="VIR">
<p>Vir Biotechnology, Inc. Common Stock (VIR) has no currently recruiting or active clinical trials where it is listed as lead sponsor on ClinicalTrials.gov.</p>
<p>VIR has 4 Form 4 insider filings recorded at the SEC in the past 30 days<sup><a href="#fn-1">[1]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">SEC EDGAR · 0001706431 (2026-04-11) <a href="https://efts.sec.gov/LATEST/search-index?q=%22VIR%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-03-12&amp;enddt=2026-04-11" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>